NASDAQ:RDNT - RadNet Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $14.75 -0.05 (-0.34 %) (As of 07/15/2018 02:56 PM ET)Previous Close$14.75Today's Range$14.70 - $14.9552-Week Range$7.45 - $15.50Volume91,991 shsAverage Volume206,136 shsMarket Capitalization$711.54 millionP/E Ratio50.86Dividend YieldN/ABeta0.4 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California. Receive RDNT News and Ratings via Email Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical SymbolNASDAQ:RDNT CUSIPN/A Webwww.radnet.com Phone310-478-7808 Debt Debt-to-Equity Ratio4.90 Current Ratio1.12 Quick Ratio1.12 Price-To-Earnings Trailing P/E Ratio50.86 Forward P/E Ratio39.86 P/E Growth5.05 Sales & Book Value Annual Sales$922.19 million Price / Sales0.77 Cash Flow$1.7601 per share Price / Cash8.38 Book Value$1.47 per share Price / Book10.03 Profitability EPS (Most Recent Fiscal Year)$0.29 Net Income$50,000.00 Net Margins-0.66% Return on Equity18.77% Return on Assets1.74% Miscellaneous Employees7,440 Outstanding Shares48,240,000Market Cap$711.54 RadNet (NASDAQ:RDNT) Frequently Asked Questions What is RadNet's stock symbol? RadNet trades on the NASDAQ under the ticker symbol "RDNT." How were RadNet's earnings last quarter? RadNet Inc. (NASDAQ:RDNT) released its quarterly earnings results on Wednesday, May, 9th. The medical research company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.04 by $0.19. The medical research company had revenue of $231.39 million for the quarter, compared to analysts' expectations of $234.32 million. RadNet had a negative net margin of 0.66% and a positive return on equity of 18.77%. The business's quarterly revenue was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.03) EPS. View RadNet's Earnings History. When is RadNet's next earnings date? RadNet is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for RadNet. What price target have analysts set for RDNT? 3 Wall Street analysts have issued twelve-month target prices for RadNet's stock. Their predictions range from $14.00 to $15.00. On average, they anticipate RadNet's stock price to reach $14.6667 in the next year. This suggests that the stock has a possible downside of 0.6%. View Analyst Ratings for RadNet. What is the consensus analysts' recommendation for RadNet? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 buy rating and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Strong Buy." Who are some of RadNet's key competitors? Some companies that are related to RadNet include Genomic Health (GHDX), Natera (NTRA), InVitae (NVTA), CareDx (CDNA), Veracyte (VCYT), Enzo Biochem (ENZ), Celcuity (CELC), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC) and OpGen (OPGN). Who are RadNet's key executives? RadNet's management team includes the folowing people: Dr. Howard G. Berger M.D., Chairman, Pres, CEO & Treasurer (Age 72)Mr. Mark D. Stolper, Exec. VP & CFO (Age 47)Mr. Jeffrey L. Linden, Exec. VP & Gen. Counsel (Age 75)Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 62)Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 57) Has RadNet been receiving favorable news coverage? Press coverage about RDNT stock has trended somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. RadNet earned a news sentiment score of 0.18 on Accern's scale. They also gave media stories about the medical research company an impact score of 45.82 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. Who are RadNet's major shareholders? RadNet's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Campbell & CO Investment Adviser LLC (0.02%). Company insiders that own RadNet stock include David L Swartz, Jeffrey L Linden, John V Crues, Lawrence L Levitt, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock, Norman R Hames, Sandy Nyholm Kaminsky and Stephen M Forthuber. View Institutional Ownership Trends for RadNet. Which major investors are selling RadNet stock? RDNT stock was sold by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. Company insiders that have sold RadNet company stock in the last year include David L Swartz, Jeffrey L Linden, John V Crues, Lawrence L Levitt, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock, Norman R Hames, Sandy Nyholm Kaminsky and Stephen M Forthuber. View Insider Buying and Selling for RadNet. How do I buy shares of RadNet? Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is RadNet's stock price today? One share of RDNT stock can currently be purchased for approximately $14.75. How big of a company is RadNet? RadNet has a market capitalization of $711.54 million and generates $922.19 million in revenue each year. The medical research company earns $50,000.00 in net income (profit) each year or $0.29 on an earnings per share basis. RadNet employs 7,440 workers across the globe. How can I contact RadNet? RadNet's mailing address is 1510 COTNER AVENUE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected] MarketBeat Community Rating for RadNet (NASDAQ RDNT)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 213 (Vote Outperform)Underperform Votes: 177 (Vote Underperform)Total Votes: 390MarketBeat's community ratings are surveys of what our community members think about RadNet and other stocks. Vote "Outperform" if you believe RDNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDNT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?